TACT: Disodium EDTA Chelation May Benefit Patients Post-MI

The 10-component disodium ethylene diamine tetra acetic acid (EDTA) chelation and ascorbate regimen could potentially benefit patients already on evidence-based therapy following myocardial infarction (MI), according to results from the TACT trial presented on Nov. 4 as part of AHA 2012 in Los Angeles, Ca.

The study, which followed 1,708 post-MI patients for an average of four years at 134 sites in the US and Canada between September 2003 and October 2010, found that disodium EDTA chelation resulted in a slightly decreased percentage of all cause mortality, MI, stroke, coronary revascularization and hospitalization for angina of 26.5 percent, compared to 30 percent with placebo (p .035). The most common outcome for both disodium EDTA chelation and placebo patients was coronary revascularization, with 130 patients in the chelation group and 157 in the placebo group needing to undergo the procedure.

Additional Resources

According to the study investigators, disodium EDTA chelation "appears to be safe" within the safety net provided by TACT. However, they note that the findings are "unexpected" and recommend additional research to confirm or refute the results and explore possible mechanisms for therapy. "TACT does not constitute evidence to recommend the clinical application of chelation therapy," they said.

< Back to Listings